Luis E. Raez

13.0k total citations
224 papers, 4.6k citations indexed

About

Luis E. Raez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Luis E. Raez has authored 224 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Oncology, 130 papers in Pulmonary and Respiratory Medicine and 61 papers in Molecular Biology. Recurrent topics in Luis E. Raez's work include Lung Cancer Treatments and Mutations (114 papers), Cancer Genomics and Diagnostics (45 papers) and Lung Cancer Research Studies (43 papers). Luis E. Raez is often cited by papers focused on Lung Cancer Treatments and Mutations (114 papers), Cancer Genomics and Diagnostics (45 papers) and Lung Cancer Research Studies (43 papers). Luis E. Raez collaborates with scholars based in United States, Belgium and Peru. Luis E. Raez's co-authors include Edgardo S. Santos, Christian Rolfo, Caio Rocha‐Lima, Rakesh Singal, Heloisa P. Soares, Eckhard R. Podack, Rossana Ruiz, Ignacio Gil‐Bazo, James J. Schlesselman and Joseph D. Rosenblatt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Luis E. Raez

201 papers receiving 4.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luis E. Raez United States 37 2.2k 1.8k 1.7k 1.2k 573 224 4.6k
Anna Spreafico Canada 31 2.3k 1.0× 1.2k 0.7× 1.2k 0.7× 591 0.5× 377 0.7× 229 3.8k
Charu Aggarwal United States 35 2.6k 1.2× 889 0.5× 1.9k 1.1× 801 0.7× 341 0.6× 202 4.1k
Francesco Caponigro Italy 28 2.3k 1.0× 2.0k 1.1× 1.2k 0.7× 552 0.5× 594 1.0× 101 4.6k
Eric X. Chen Canada 42 2.5k 1.1× 1.8k 1.0× 1.6k 0.9× 878 0.8× 1.6k 2.8× 162 5.7k
William N. William United States 33 2.0k 0.9× 893 0.5× 1.5k 0.8× 559 0.5× 901 1.6× 109 4.0k
Ralph Zinner United States 32 2.0k 0.9× 1.6k 0.9× 1.5k 0.9× 771 0.7× 652 1.1× 161 4.0k
Scott A. Laurie Canada 36 4.3k 1.9× 1.2k 0.7× 3.3k 1.9× 685 0.6× 1.2k 2.1× 163 6.3k
David Boulware United States 41 1.5k 0.7× 1.6k 0.9× 924 0.5× 845 0.7× 1.7k 3.0× 122 5.4k
Raanan Berger Israel 34 4.2k 1.9× 2.2k 1.2× 1.9k 1.1× 1.2k 1.0× 891 1.6× 160 7.2k
Antonio Jimeno United States 36 3.1k 1.4× 2.3k 1.3× 1.4k 0.8× 921 0.8× 552 1.0× 128 5.2k

Countries citing papers authored by Luis E. Raez

Since Specialization
Citations

This map shows the geographic impact of Luis E. Raez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis E. Raez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis E. Raez more than expected).

Fields of papers citing papers by Luis E. Raez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis E. Raez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis E. Raez. The network helps show where Luis E. Raez may publish in the future.

Co-authorship network of co-authors of Luis E. Raez

This figure shows the co-authorship network connecting the top 25 collaborators of Luis E. Raez. A scholar is included among the top collaborators of Luis E. Raez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis E. Raez. Luis E. Raez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Meric‐Bernstam, Funda, Martin Gutierrez, Enrique Sanz‐García, et al.. (2025). Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications. 5(9). 1664–1673. 1 indexed citations
3.
Khan, Atif J., et al.. (2024). P3.03I.16 Treatment Outcomes in Patients who Received Bevacizumab Therapy for Radiation Induced Brain Necrosis. Journal of Thoracic Oncology. 19(10). S316–S316.
4.
5.
Raez, Luis E., Hyunseok Kang, Yuichiro Ohe, et al.. (2024). Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial. ESMO Open. 9(5). 103444–103444. 3 indexed citations
6.
Alvarez-Pinzon, Andrés M., et al.. (2024). NTRK Therapy among Different Types of Cancers, Review and Future Perspectives. International Journal of Molecular Sciences. 25(4). 2366–2366. 12 indexed citations
7.
Nagasaka, Misako, Yasmine Baca, Joanne Xiu, et al.. (2023). Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Translational Oncology. 36. 101744–101744. 13 indexed citations
8.
Sands, Jacob, Sumithra J. Mandrekar, David Kozono, et al.. (2021). Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO). Immunotherapy. 13(9). 727–734. 17 indexed citations
9.
Nagasaka, Misako, Vijendra K. Singh, Yasmine Baca, et al.. (2021). The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 52–59. 21 indexed citations
10.
Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2020). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy. Clinical Cancer Research. 27(4). 1019–1028. 83 indexed citations
11.
Raez, Luis E., et al.. (2020). Cardiac Tumors are not always Myxomas. 5(1).
12.
Araujo, Jhajaira M., et al.. (2020). Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer. Hematology/Oncology and Stem Cell Therapy. 14(3). 192–198. 5 indexed citations
13.
Castellanos-Rizaldos, Elena, Dominik G. Grimm, Vasisht Tadigotla, et al.. (2018). Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients. Clinical Cancer Research. 24(12). 2944–2950. 171 indexed citations
14.
Castrellon, Aurelio, et al.. (2017). Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer. 2(1). 1–5. 1 indexed citations
15.
Raez, Luis E.. (2017). Case Report: Detection of c797s as a Mechanism of Resistance in a Patient With Lung Cancer With EGFR Mutations. 13(9). 1 indexed citations
16.
Castrellon, Aurelio, et al.. (2017). Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer. Hematology/Oncology and Stem Cell Therapy. 11(1). 30–33. 1 indexed citations
17.
Santos, Edgardo S., et al.. (2016). Genomic Tissue Analysis and Liquid Biopsy Profiles from Patients Diagnosed with Advanced Adenocarcinoma of the Lung. 1(1). 5 indexed citations
18.
Raez, Luis E., Kyriakos P. Papadopoulos, Alejandro D. Ricart, et al.. (2012). A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 71(2). 523–530. 411 indexed citations
19.
Argiris, Athanassios, Michalis V. Karamouzis, William E. Gooding, et al.. (2011). Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal of Clinical Oncology. 29(9). 1140–1145. 84 indexed citations
20.
Raez, Luis E., Virginia K. Langmuir, Alejandro D. Ricart, et al.. (2006). Phase I trial of glycolitic inhibition with 2-deoxyglucose and docetaxel for patients with solid tumors. Cancer Research. 66. 121–122. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Spreafico Breakdown of academic impact, for papers by Charu Aggarwal Breakdown of academic impact, for papers by Francesco Caponigro Breakdown of academic impact, for papers by Eric X. Chen Breakdown of academic impact, for papers by William N. William Breakdown of academic impact, for papers by Ralph Zinner Breakdown of academic impact, for papers by Scott A. Laurie Breakdown of academic impact, for papers by David Boulware Breakdown of academic impact, for papers by Raanan Berger Breakdown of academic impact, for papers by Antonio Jimeno
Rankless by CCL
2026